- Home
- XPEL vs FTRE Comparison
XPEL vs FTRE Comparison
Compare XPEL & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEL | FTRE |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | XPEL | FTRE |
|---|---|---|
| Price | $49.04 | $18.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $56.00 | $14.06 |
| AVG Volume (30 Days) | 238.1K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.12 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | $476,200,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $11.98 | $3.09 |
| P/E Ratio | $46.52 | ★ N/A |
| Revenue Growth | ★ 13.27 | 1.00 |
| 52 Week Low | $31.50 | $7.40 |
| 52 Week High | $55.91 | $21.39 |
Technical Indicators
Market Signals| Indicator | XPEL | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 50.97 |
| Support Level | $45.60 | $15.69 |
| Resistance Level | $51.66 | $21.39 |
| Average True Range (ATR) | 2.18 | 1.32 |
| MACD | 0.55 | -0.13 |
| Stochastic Oscillator | 74.80 | 25.59 |
Price Performance
Historical ComparisonAbout XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.